Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy

Rick Proschmann, Christoph Baldow, Tino Rothe, Meinolf Suttrop, Christian Thiede, Josephine T. Tauer, Martin C. Müller, Andreas Hochhaus, Ingo Roeder, and Ingmar Glauche

Disclosures: M.S. and C.T. received research support from Novartis. I.R. and I.G. receive research funding from Bristol-Myers Squibb. A.H. received research support from Novartis, Bristol-Myers Squibb, Ariad, Pfizer. C.T. is part owner of AgenDix GmbH, which performs molecular diagnostics. The remaining authors declare no competing financial interests.

Contributions: J.T.T., C.T., M.S., A.H. and M.M. provided the clinical and/or molecular data; I.R. and I.G. conceived the mathematical model; R.P., T.R., C.B. and I.G. conducted the analysis and simulations; M.S., I.G., and I.R. provided supervision; C.T., I.R., A.H. provided advice and input for modeling and data analysis; R.P., I.G., C.B. and M.S. drafted the paper; I.R. critically reviewed the paper and all authors read and approved the final version of the paper.